Calibrant works in close collaboration with partners in the biotechnology and pharmaceutical industries to apply the Gemini™ platform to specific therapeutic discovery and development goals. Calibrant provides value to our partners through the discovery of novel drug targets, improved pre-clinical and clinical development efficiencies, increased safety and efficacy, and the identification of predictive markers.

Beginning in December 2007, Calibrant offers a Commercial Access Program (CAP) for potential partners interested in evaluating the Gemini™proteomics platform for specific project goals. Where appropriate, Calibrant also provides access to the Gemini™ platform on a fee-for-service basis. For more information on the CAP program, or to inquire about partnership opportunities, please contact us.